Overview
Rare disease company reported 2025 net product sales of $521 mln, up from 2024
Company expects 2026 global net product sales of $630 mln to $650 mln
Company completed acquisition of Bluejay Therapeutics, adding brelovitug for HDV
Outlook
Mirum expects 2026 global net product sales of $630 mln to $650 mln
Volixibat VISTAS study topline data expected in Q2 2026
LIVMARLI EXPAND study topline data expected in Q4 2026
Result Drivers
LIVMARLI SALES GROWTH - LIVMARLI net product sales increased 69% year-over-year in the U.S., contributing significantly to 2025 revenue growth
GLOBAL EXPANSION - Expanded commercial access to 33 countries, enhancing global sales reach
BLUEJAY ACQUISITION - Acquisition of Bluejay Therapeutics added brelovitug for HDV, enhancing pipeline
Company press release: ID:nBwc886mla
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Product Sales | $148.93 mln | ||
Q4 Net Income | -$5.73 mln | ||
Q4 Operating Expenses | $153.50 mln | ||
Q4 Operating Income | -$4.57 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Mirum Pharmaceuticals Inc is $112.50, about 4.7% above its February 24 closing price of $107.48
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)